Sutro Biopharma, Inc. announced that Chief Medical Officer, Arturo Molina, M.D., M.S., F.A.C.P. will be leaving the company to pursue other opportunities, effective November 4, 2022. Sutro will continue its executive search for a new CMO. In the interim, Bill Newell CEO, with support from Sutro's senior clinical development team, will oversee all clinical activities and related functions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | -4.23% | +3.82% | -4.90% |
May. 13 | Sutro Biopharma Q1 Loss Widens, Revenue Rises | MT |
May. 13 | Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q1 Revenue $13M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.90% | 348M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- STRO Stock
- News Sutro Biopharma, Inc.
- Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer